RxDoctor Payments Data

Donald Forest, MD

Internal Medicine · Denver, CONPI 1588664841

Payments from drug & device makers

$679in general payments, 2019–2025

Across 35 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$263
  • Novo Nordisk$78
  • GSK$71
  • Pfizer$68
  • Amgen$54
  • Astellas Pharma US Inc$38
  • plus $107 from 6 others

What the payments were for

  • Food & beverage$679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)12$263
Novo Nordisk4$78
GSK4$71
Pfizer4$68
Amgen(2 entities)3$54
Astellas Pharma US Inc2$38
Takeda Pharmaceuticals U.S.A., Inc.1$27
Hologic Sales And Service, LLC1$21
VBI Vaccine (delaware) Inc.1$16
Clarus Therapeutics Inc.1$16
Lilly USA, LLC1$15
Medicure Pharma Inc.1$13

How this compares

$679 in reported general payments places this provider in the 80th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$76,636
Medicare patients
167
Services billed
1,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban45$67,982
EliquisApixaban45$65,509
TrulicityDulaglutide11$25,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$24,992
JardianceEmpagliflozin12$21,664
MyrbetriqMirabegron21$18,674
JanuviaSitagliptin Phosphate14$15,522
Spiriva RespimatTiotropium Bromide17$14,077
Testosterone22$10,222
ShingrixVaricella-Zoster Ge/As01b/Pf24$5,271
SynthroidLevothyroxine Sodium33$2,588
Memantine Hcl ErMemantine Hcl13$2,501
Levothyroxine Sodium227$2,424
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,406
Atorvastatin Calcium274$1,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$65,50945 claims
GSKTrelegy Ellipta, Shingrix$71$30,26244 claims
Lilly USA, LLCTrulicity$15$25,39911 claims
Astellas Pharma US IncMyrbetriq$38$18,67421 claims
AbbVieSynthroid$263$2,58833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →